Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

BACKGROUND: The safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine (Sub/MF59™; FLUAD(®), Novartis Vaccines) was evaluated among elderly Chinese subjects (≥ 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1–14 days post-vaccination, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Rongcheng, Fang, Hanhua, Li, Yanping, Liu, Youping, Pellegrini, Michele, Podda, Audino
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291031/
https://www.ncbi.nlm.nih.gov/pubmed/18289372
http://dx.doi.org/10.1186/1742-4933-5-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291031/
https://www.ncbi.nlm.nih.gov/pubmed/18289372
http://dx.doi.org/10.1186/1742-4933-5-2

Ejemplares similares